ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Glipizide: Drug information

Glipizide: Drug information
(For additional information see "Glipizide: Patient drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
Brand Names: US
  • glipiZIDE XL;
  • Glucotrol XL;
  • Glucotrol [DSC]
Brand Names: Canada
  • Glucotrol XL
Pharmacologic Category
  • Antidiabetic Agent, Sulfonylurea
Dosing: Adult
Diabetes mellitus, type 2, treatment

Diabetes mellitus, type 2, treatment:

Note: May be used as an adjunctive agent or alternative monotherapy for patients in whom initial therapy with lifestyle intervention and metformin failed or who cannot take metformin. Sulfonylureas are associated with a greater risk of hypoglycemia than other noninsulin antidiabetic agents; if one is chosen, a sulfonylurea with a lower relative risk of hypoglycemia (eg, glipizide, glimepiride) is preferred (Ref).

Immediate release:

Oral: Initial: 2.5 to 5 mg once daily 30 minutes before the first main meal; in patients whose glycemic levels are close to goal, use lower initial doses (eg, 2.5 mg once daily) to reduce the risk of hypoglycemia (Ref). In patients with severe hyperglycemia (eg, fasting glucose >250 mg/dL, HbA1c >9%) without ketonuria or spontaneous weight loss and in whom type 1 diabetes is unlikely, some experts use a higher initial dose of 10 mg twice daily 30 minutes before meals (Ref).

Dosage adjustment: May increase dose in 2.5 to 5 mg increments every 1 to 4 weeks if needed to achieve glycemic goals; usual maintenance dose: 2.5 to 10 mg/day (maximum effective dose: 20 mg/day) (Ref). Note: Increasing dosage to the labeled maximum dose of 40 mg/day has not been shown to improve glycemic control (Ref). Administer daily doses >15 mg/day in 2 divided doses given 30 minutes before meals; may also divide the daily dose into 2 doses if once-daily dosing does not provide adequate glycemic control.

Extended release:

Oral: Initial: 2.5 to 5 mg once daily with the first main meal; in patients whose glycemic levels are close to goal, use lower initial doses (eg, 2.5 mg once daily) to reduce the risk of hypoglycemia (Ref).

Dosage adjustment: May increase dose in 2.5 to 5 mg increments every 1 to 4 weeks if needed to achieve glycemic goals; usual maintenance dose: 5 to 10 mg/day (maximum: 20 mg/day) (Ref).

Glipizide conversion recommendations:

Conversion from IR to ER glipizide: May switch the IR total daily dose to the nearest equivalent daily dose of the ER tablet and administer once daily.

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.

Altered kidney function:

Note: Glipizide is a preferred sulfonylurea in patients with chronic kidney disease (it has inactive metabolites) (Ref); however, conservative initial and maintenance dosing is recommended to avoid hypoglycemic events (Ref):

Oral: Immediate-release and extended-release tablets:

eGFR ≥50 mL/minute/1.73 m2: No dose adjustment necessary.

eGFR 10 to <50 mL/minute/1.73 m2: Initial: 2.5 mg once daily. May cautiously titrate based on glycemic control up to a maximum 20 mg/day (Ref).

eGFR <10 mL/minute/1.73 m2: Avoid use if possible (Ref). If necessary, initial dose of 2.5 mg once daily, may cautiously titrate based on glycemic control up to a maximum of 20 mg/day (Ref).

Hemodialysis, intermittent (thrice weekly): Not likely to be dialyzable (Ref).

Dose for eGFR <10 mL/minute, use with caution (Ref).

Peritoneal dialysis: Dose for eGFR <10 mL/minute, use with caution (Ref).

Dosing: Hepatic Impairment: Adult

Immediate release: Oral: Initial: 2.5 mg once daily; maintenance dosing should be conservative to avoid hypoglycemia

Extended release: Oral: Initial: 2.5 mg once daily; maintenance dosing should be conservative to avoid hypoglycemia

Dosing: Older Adult

Diabetes mellitus, type 2, treatment (alternative agent):

Note: Use of sulfonylureas (eg, glipizide) is associated with increased risk of hypoglycemia. The American Diabetes Association suggests using sulfonylureas with caution, and notes preference for glipizide (or glimepiride) due to lower relative risk of hypoglycemia compared to other sulfonylureas (Ref).

Immediate release: Oral: Initial: 2.5 mg once daily; consider titrating by 2.5 to 5 mg/day at 1- to 2-week intervals. Maintenance dosing should be conservative to avoid hypoglycemia.

Extended release: Oral: Initial: 2.5 mg once daily; maintenance dosing should be conservative to avoid hypoglycemia.

Adverse Reactions (Significant): Considerations
Cardiovascular effects

Product labeling states oral hypoglycemic drugs may be associated with an increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin. Data to support this association are limited, and several studies, including a large prospective trial (Ref), have not supported an association. In patients with established atherosclerotic cardiovascular disease, other agents are preferred (Ref).

Hypoglycemia

Use of sulfonylureas, including glipizide, may result in hypoglycemia, which may be severe. Shorter-acting sulfonylureas (eg, glipizide, gliclazide) are associated with a lesser risk of hypoglycemia as compared to their longer-acting counterparts and/or agents with active metabolites (eg, glimepiride, glyburide) (Ref); the duration of glipizide-induced hypoglycemia may be prolonged in patients receiving an extended-release formulation (Ref). In general, sulfonylureas are associated with a higher risk of hypoglycemia when compared to other non-insulin antihyperglycemic agents (eg, metformin, dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists, thiazolidinediones) (Ref).

Mechanism: Dose-dependent (Ref); related to the pharmacologic action. Sulfonylureas stimulate the release of insulin from the pancreas.

Onset: Rapid; may occur after a single dose (Ref). Timing may be impacted by concomitant use of other antihyperglycemic medications, nutritional status (eg, caloric intake), dose titration, or accumulation.

Risk factors:

• Deficient caloric intake or malnourishment

• Rigorous or prolonged exercise

• Ingestion of alcohol

• Concomitant use of other antihyperglycemic agents (Ref)

• Concomitant use of antibiotics (Ref), fibrates (eg, gemfibrozil (Ref)), or warfarin (Ref)

• Older adults (eg, ≥65 years of age (Ref))

• Patients with poor general health

• Patients with impaired kidney function; Note: In patients with impaired kidney function, glipizide may be less likely to cause hypoglycemia as compared to other sulfonylureas as glipizide is metabolized by the liver and excreted in the urine as inactive metabolites. (Ref)

• Patients with impaired liver function

• Patients with pituitary insufficiency

• Patients with or at risk for hypoglycemia awareness; risk factors may include:

- Autonomic neuropathy

- Older adults

- Concomitant use of beta-blockers or other sympatholytic agents (Ref)

- Recent hypoglycemia (hypoglycemia-associated autonomic failure) (Ref)

- Patients that are heterozygous or homozygous for CYP2C9 variant alleles (*2 or *3) with subsequent decreased enzyme activity may be at an increased risk for sulfonylurea-induced hypoglycemia, especially with use of gliclazide (Ref).

Sulfonamide allergy

The FDA-approved product labeling for many medications containing a sulfonamide chemical group includes a broad contraindication in patients with a prior allergic reaction to any sulfonamide. Although there is a potential for cross-reactivity between antibiotic sulfonamides, concerns for cross-reactivity have previously extended to all compounds containing the sulfonamide structure (SO2NH2). An expanded understanding of allergic mechanisms indicates cross-reactivity between antibiotic sulfonamides and nonantibiotic sulfonamides is unlikely to occur (Ref).

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults and may include incidences from dosages exceeding the recommended dose.

1% to 10%:

Endocrine & metabolic: Hypoglycemia (3%)

Gastrointestinal: Abdominal pain (1%), constipation (<3%), diarrhea (1% to 5%), dyspepsia (<3%), flatulence (3%), nausea (<3%), vomiting (<3%)

Hypersensitivity: Hypersensitivity reaction (<2%; including eczema, erythema of skin, maculopapular rash, morbilliform rash, pruritus, urticaria)

Nervous system: Dizziness (2% to 7%), drowsiness (2%), headache (2%), nervousness (4%), tremor (4%)

Frequency not defined:

Endocrine & metabolic: Increased lactate dehydrogenase

Hepatic: Increased serum alkaline phosphatase, increased serum aspartate aminotransferase

Renal: Increased blood urea nitrogen, increased serum creatinine

Postmarketing:

Dermatologic: Skin rash

Endocrine & metabolic: Hyponatremia, SIADH

Hematologic & oncologic: Agranulocytosis, aplastic anemia, hemolytic anemia, leukopenia, pancytopenia, thrombocytopenia

Hepatic: Cholestatic jaundice, hepatic injury (can be induced with alcohol consumption) (Ilario 200), hepatic porphyria, jaundice

Neuromuscular & skeletal: Myopathy (Das 2016)

Miscellaneous: Disulfiram-like reaction

Contraindications

Hypersensitivity to glipizide, sulfonamide derivatives, or any component of the formulation; type 1 diabetes mellitus; diabetic ketoacidosis (with or without coma).

Note: Although the FDA-approved product labeling states this medication is contraindicated in patients with hypersensitivity to sulfonamide-containing drugs, the scientific basis of this cross-sensitivity has been challenged. See “Warnings/Precautions” for more detail.

Warnings/Precautions

Disease-related concerns:

• Bariatric surgery:

– Altered absorption: Use IR formulations after surgery to minimize the potential effects of bypassing stomach and proximal small bowel with gastric bypass or more rapid gastric emptying and proximal small bowel transit with sleeve gastrectomy (Apovian 2015). ER formulations may have altered release and absorption patterns after gastric bypass or sleeve gastrectomy (but not gastric band). Compared to control, Tmax in a gastric bypass cohort administered tolbutamide was significantly shorter (1.4 ± 1.8 vs 5.1 ± 1.7 hours; P < 0.001), while Cmax and AUC0- ∞ were not altered (Tandra 2013).

– Hypoglycemia: Use an antidiabetic agent without the potential for hypoglycemia if possible; hypoglycemia may occur after gastric bypass, sleeve gastrectomy, and gastric band (Mechanick 2020). Insulin secretion and sensitivity may be partially or completely restored after these procedures (gastric bypass is most effective, followed by sleeve and finally band) (Korner 2009; Peterli 2012). First-phase insulin secretion and hepatic insulin sensitivity have been shown to be significantly improved in the immediate days after gastric bypass and sleeve gastrectomy. The restorative effects of these procedures on peripheral insulin sensitivity may occur later in the 3- to 12-month period postsurgery (Mingrone 2016).

– Weight gain: Evaluate risk vs benefit and consider alternative therapy after gastric bypass, sleeve gastrectomy, and gastric banding; weight gain may occur (Apovian 2015).

• Glucose-6-phosphate dehydrogenase (G6PD) deficiency: Patients with G6PD deficiency may be at an increased risk of sulfonylurea-induced hemolytic anemia; however, cases have also been described in patients without G6PD deficiency during postmarketing surveillance. Use with caution and consider a nonsulfonylurea alternative in patients with G6PD deficiency.

• Hepatic impairment: Use with caution in patients with hepatic impairment.

• Renal impairment: Use with caution in patients with renal impairment.

• Stress-related states: It may be necessary to discontinue therapy and administer insulin if the patient is exposed to stress (fever, trauma, infection, surgery).

Dosage form specific issues:

• GI tract stricture/narrowing: The extended release formulation consists of drug within a nondeformable matrix; following drug release/absorption, the matrix/shell is expelled in the stool. The use of nondeformable products in patients with known stricture/narrowing of the GI tract has been associated with symptoms of obstruction. Avoid use of extended release tablets (Glucotrol XL) in patients with severe gastrointestinal narrowing or esophageal dysmotility.

Other warnings/precautions:

• Appropriate use: Not for use in patients with diabetic ketoacidosis (DKA) or patients with type 1 diabetes mellitus.

• Hospitalized patients: Consider temporary discontinuation of noninsulin antidiabetic agents and initiation or continuation of insulin therapy during hospitalization (ADA 2023). In noncritically ill hospitalized patients, continued use of glipizide may be considered if there are no contraindications, regular nutritional intake is expected, and blood glucose is well controlled; close monitoring and subsequent dosage adjustments are recommended (ADA/AACE [Moghissi 2009]; Bogun 2013; Inzucchi 2006).

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Tablet, Oral:

Glucotrol: 5 mg [DSC]

Glucotrol: 10 mg [DSC] [scored]

Generic: 2.5 mg, 5 mg, 10 mg

Tablet Extended Release 24 Hour, Oral:

glipiZIDE XL: 2.5 mg, 5 mg, 10 mg

Glucotrol XL: 2.5 mg, 5 mg, 10 mg

Generic: 2.5 mg, 5 mg, 10 mg

Generic Equivalent Available: US

Yes

Pricing: US

Tablet, 24-hour (glipiZIDE ER Oral)

2.5 mg (per each): $0.41

5 mg (per each): $0.41

10 mg (per each): $0.81

Tablet, 24-hour (Glucotrol XL Oral)

2.5 mg (per each): $0.47

5 mg (per each): $0.47

10 mg (per each): $0.85

Tablets (glipiZIDE Oral)

2.5 mg (per each): $1.84

5 mg (per each): $0.35 - $0.40

10 mg (per each): $0.60 - $0.67

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Tablet Extended Release 24 Hour, Oral:

Glucotrol XL: 5 mg, 10 mg

Administration: Adult

Oral: Note: Patients that are NPO or require decreased caloric intake may need doses held to avoid hypoglycemia.

Immediate release: Administer 30 minutes before a meal (preferably before breakfast if once-daily dosing) to achieve greatest reduction in postprandial hyperglycemia.

Extended release: Administer with breakfast or the first meal of the day; swallow tablets whole, do not chew, divide or crush.

Bariatric surgery: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. Switch to IR tablet. Avoid use of sulfonylureas immediately postoperative. Hormonal changes induced by surgery and low carbohydrate immediate postop diet could lead to profound hypoglycemia if sulfonylureas are administered.

Use: Labeled Indications

Diabetes mellitus, type 2, treatment: Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

Medication Safety Issues
Sound-alike/look-alike issues:

GlipiZIDE may be confused with glimepiride, glyBURIDE

Glucotrol may be confused with Glucophage, Glucotrol XL, glyBURIDE, GlycoTrol (dietary supplement)

High alert medication:

The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.

Older Adult: High-Risk Medication:

Avoid routine use of sulfonylureas due to increased risk of hypoglycemia; however, if a sulfonylurea is needed, one with a lower relative risk of hypoglycemia (eg, gliclazide, glipizide, glimepiride) is preferred (ADA 2023; Beers Criteria [AGS 2023]; Diabetes Canada).

Metabolism/Transport Effects

Substrate of CYP2C9 (major), OATP1B1/1B3 (SLCO1B1/1B3); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

Ajmaline: Sulfonamides may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased. Risk C: Monitor therapy

Alcohol (Ethyl): Sulfonylureas may enhance the adverse/toxic effect of Alcohol (Ethyl). A flushing reaction may occur. Risk C: Monitor therapy

Alpelisib: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers). Risk C: Monitor therapy

Alpha-Glucosidase Inhibitors: May enhance the hypoglycemic effect of Sulfonylureas. Management: Consider a decrease in sulfonylurea dose when initiating therapy with an alpha-glucosidase inhibitor and monitor patients for hypoglycemia. Risk D: Consider therapy modification

Alpha-Lipoic Acid: May enhance the hypoglycemic effect of Antidiabetic Agents. Risk C: Monitor therapy

Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). Risk X: Avoid combination

Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). Risk C: Monitor therapy

Amiodarone: May enhance the hypoglycemic effect of Sulfonylureas. Risk C: Monitor therapy

Androgens: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Risk C: Monitor therapy

Antidiabetic Agents: May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents. Risk C: Monitor therapy

Beta-Blockers (Beta1 Selective): May enhance the hypoglycemic effect of Antidiabetic Agents. Risk C: Monitor therapy

Beta-Blockers (Nonselective): May enhance the hypoglycemic effect of Sulfonylureas. Beta-Blockers (Nonselective) may diminish the therapeutic effect of Sulfonylureas. Risk C: Monitor therapy

Bortezomib: May enhance the therapeutic effect of Antidiabetic Agents. Bortezomib may diminish the therapeutic effect of Antidiabetic Agents. Risk C: Monitor therapy

Carbocisteine: Sulfonylureas may enhance the adverse/toxic effect of Carbocisteine. Specifically, sulfonylureas may enhance adverse effects of alcohol that is present in liquid formulations of carbocisteine-containing products. Risk C: Monitor therapy

Chloramphenicol (Systemic): May increase the serum concentration of Sulfonylureas. Risk C: Monitor therapy

Cimetidine: May increase the serum concentration of GlipiZIDE. Risk C: Monitor therapy

Clarithromycin: May enhance the hypoglycemic effect of Sulfonylureas. Risk C: Monitor therapy

Colesevelam: May decrease the serum concentration of GlipiZIDE. Management: Administer glipizide at least 4 hours prior to colesevelam. Risk D: Consider therapy modification

CYP2C9 Inducers (Moderate): May decrease the serum concentration of Sulfonylureas. Risk C: Monitor therapy

CYP2C9 Inhibitors (Moderate): May increase the serum concentration of Sulfonylureas. Risk C: Monitor therapy

Dexketoprofen: May enhance the adverse/toxic effect of Sulfonamides. Risk C: Monitor therapy

Dipeptidyl Peptidase-IV Inhibitors: May enhance the hypoglycemic effect of Sulfonylureas. Management: Consider a decrease in sulfonylurea dose when initiating therapy with a dipeptidyl peptidase-IV inhibitor and monitor patients for hypoglycemia. Risk D: Consider therapy modification

Direct Acting Antiviral Agents (HCV): May enhance the hypoglycemic effect of Antidiabetic Agents. Risk C: Monitor therapy

Elexacaftor, Tezacaftor, and Ivacaftor: May increase the serum concentration of GlipiZIDE. Risk C: Monitor therapy

Etilefrine: May diminish the therapeutic effect of Antidiabetic Agents. Risk C: Monitor therapy

Fibric Acid Derivatives: May enhance the hypoglycemic effect of Sulfonylureas. Risk C: Monitor therapy

Glucagon-Like Peptide-1 Agonists: May enhance the hypoglycemic effect of Sulfonylureas. Management: Consider sulfonylurea dose reductions when used in combination with glucagon-like peptide-1 agonists. Risk D: Consider therapy modification

Guanethidine: May enhance the hypoglycemic effect of Antidiabetic Agents. Risk C: Monitor therapy

Herbal Products with Glucose Lowering Effects: May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents. Risk C: Monitor therapy

Hyperglycemia-Associated Agents: May diminish the therapeutic effect of Antidiabetic Agents. Risk C: Monitor therapy

Hypoglycemia-Associated Agents: May enhance the hypoglycemic effect of other Hypoglycemia-Associated Agents. Risk C: Monitor therapy

Hypoglycemia-Associated Agents: Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemia-Associated Agents. Risk C: Monitor therapy

Indobufen: May increase the serum concentration of GlipiZIDE. Risk C: Monitor therapy

Lumacaftor and Ivacaftor: May decrease the serum concentration of CYP2C9 Substrates (High Risk with Inhibitors or Inducers). Lumacaftor and Ivacaftor may increase the serum concentration of CYP2C9 Substrates (High Risk with Inhibitors or Inducers). Risk C: Monitor therapy

Maitake: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Risk C: Monitor therapy

Mecamylamine: Sulfonamides may enhance the adverse/toxic effect of Mecamylamine. Risk X: Avoid combination

Methoxsalen (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Methoxsalen (Systemic). Risk C: Monitor therapy

Metreleptin: May enhance the hypoglycemic effect of Sulfonylureas. Management: Sulfonylurea dosage adjustments (including potentially large decreases) may be required to minimize the risk for hypoglycemia with concurrent use of metreleptin. Monitor closely for signs or symptoms of hypoglycemia. Risk D: Consider therapy modification

Miconazole (Oral): May enhance the hypoglycemic effect of Sulfonylureas. Miconazole (Oral) may increase the serum concentration of Sulfonylureas. Risk C: Monitor therapy

Mitiglinide: May enhance the adverse/toxic effect of Sulfonylureas. Risk X: Avoid combination

Monoamine Oxidase Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Risk C: Monitor therapy

Pegvisomant: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Risk C: Monitor therapy

Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. Risk C: Monitor therapy

Posaconazole: May enhance the hypoglycemic effect of GlipiZIDE. Posaconazole may increase the serum concentration of GlipiZIDE. Risk C: Monitor therapy

Probenecid: May increase the serum concentration of Sulfonylureas. Risk C: Monitor therapy

Prothionamide: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Risk C: Monitor therapy

Quinolones: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Quinolones may diminish the therapeutic effect of Agents with Blood Glucose Lowering Effects. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use. Risk C: Monitor therapy

RaNITIdine (Withdrawn from US Market): May increase the serum concentration of GlipiZIDE. Risk C: Monitor therapy

Rifapentine: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers). Risk C: Monitor therapy

Ritodrine: May diminish the therapeutic effect of Antidiabetic Agents. Risk C: Monitor therapy

Salicylates: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Risk C: Monitor therapy

Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Risk C: Monitor therapy

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: May enhance the hypoglycemic effect of Sulfonylureas. Management: Consider a decrease in sulfonylurea dose when initiating therapy with a sodium-glucose cotransporter 2 (SGLT2) inhibitor and monitor patients for hypoglycemia. Risk D: Consider therapy modification

Sulfonamide Antibiotics: May enhance the hypoglycemic effect of Sulfonylureas. Risk C: Monitor therapy

Tetracyclines: May enhance the hypoglycemic effect of Sulfonylureas. Risk C: Monitor therapy

Tezacaftor and Ivacaftor: May increase the serum concentration of GlipiZIDE. Risk C: Monitor therapy

Thiazide and Thiazide-Like Diuretics: May diminish the therapeutic effect of Antidiabetic Agents. Risk C: Monitor therapy

Thiazolidinediones: May enhance the hypoglycemic effect of Sulfonylureas. Management: Consider sulfonylurea dose adjustments in patients taking thiazolidinediones and monitor for hypoglycemia. Risk D: Consider therapy modification

Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. Risk C: Monitor therapy

Vitamin K Antagonists (eg, warfarin): Sulfonylureas may enhance the anticoagulant effect of Vitamin K Antagonists. Vitamin K Antagonists may enhance the hypoglycemic effect of Sulfonylureas. Risk C: Monitor therapy

Voriconazole: May increase the serum concentration of Sulfonylureas. Risk C: Monitor therapy

Food Interactions

Ethanol: May cause rare disulfiram reactions. Management: Monitor patients.

Food: A delayed release of insulin may occur if glipizide is taken with food. Management: Immediate release tablets should be administered 30 minutes before meals to avoid erratic absorption.

Reproductive Considerations

Sulfonylureas are not recommended for patients with type 2 diabetes mellitus planning to become pregnant. Patients who could become pregnant should use effective contraception during therapy. Transition to a preferred therapy should be initiated prior to conception and contraception should be continued until glycemic control is achieved (ADA 2023; Alexopoulos 2019; Egan 2020)

Pregnancy Considerations

Glipizide was found to cross the placenta in vitro (Elliott 1994).

Severe hypoglycemia lasting 4 to 10 days has been noted in infants born to mothers taking a sulfonylurea at the time of delivery. The manufacturer recommends if glipizide is used during pregnancy, it should be discontinued at least 2 weeks before the expected delivery date.

Poorly controlled diabetes during pregnancy can be associated with an increased risk of adverse maternal and fetal outcomes, including diabetic ketoacidosis, preeclampsia, spontaneous abortion, preterm delivery, delivery complications, major malformations, stillbirth, and macrosomia. To prevent adverse outcomes, prior to conception and throughout pregnancy, maternal blood glucose and HbA1c should be kept as close to target goals as possible but without causing significant hypoglycemia (ADA 2023; Blumer 2013).

Agents other than glipizide are currently recommended to treat diabetes mellitus in pregnancy (ADA 2023).

Breastfeeding Considerations

Data from two mother-infant pairs note that glipizide was not detected in breast milk (Feig 2005).

Current guidelines note that breastfeeding is encouraged for all women, including those with diabetes (ACOG 201 2018; ADA 2023; Blumer 2013). A small snack before breastfeeding may help decrease the risk of hypoglycemia in women with pregestational diabetes (ACOG 201 2018; Reader 2004).

According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. Monitor the infant for hypoglycemia.

Dietary Considerations

Take immediate release tablets 30 minutes before meals (preferably before breakfast if once-daily dosing); extended release tablets should be taken with breakfast or the first meal of the day. Individualized medical nutrition therapy (MNT) based on ADA recommendations is an integral part of therapy.

Monitoring Parameters

Signs and symptoms of hypoglycemia (fatigue, excessive hunger, profuse sweating, numbness of extremities), blood glucose; renal function; liver function; weight (due to potential to cause weight gain).

HbA1c: Monitor at least twice yearly in patients who have stable glycemic control and are meeting treatment goals; monitor quarterly in patients in whom treatment goals have not been met, or with therapy change. Note: In patients prone to glycemic variability (eg, patients with insulin deficiency), or in patients whose HbA1c is discordant with serum glucose levels or symptoms, consider evaluating HbA1c in combination with blood glucose levels and/or a glucose management indicator (ADA 2023; KDIGO 2020).

Reference Range

Recommendations for glycemic control in patients with diabetes:

Nonpregnant adults with diabetes (AACE [Samson 2023], ADA 2023):

HbA1c: <7% (a more aggressive [<6.5%] or less aggressive [<8%] HbA1c goal may be targeted based on patient-specific characteristics). Note: In patients using a continuous glucose monitoring system, a goal of time in range >70% with time below range <4% is recommended and is similar to a goal HbA1c <7%.

Preprandial capillary blood glucose: 80 to 130 mg/dL (SI: 4.4 to 7.2 mmol/L) (more or less stringent goals may be appropriate based on patient-specific characteristics).

Peak postprandial capillary blood glucose (~1 to 2 hours after a meal): <180 mg/dL (SI: <10 mmol/L) (more or less stringent goals may be appropriate based on patient-specific characteristics).

Older adults (≥65 years of age) (ADA 2023):

Note: Consider less strict targets in patients who are using insulin and/or insulin secretagogues (sulfonylureas, meglitinides) (ES [LeRoith 2019]).

HbA1c: <7% to 7.5% (healthy); <8% (complex/intermediate health). Note: Individualization may be appropriate based on patient and caregiver preferences and/or presence of cognitive impairment. In patients with very complex or poor health (ie, limited remaining life expectancy), consider making therapy decisions based on avoidance of hypoglycemia and symptomatic hyperglycemia rather than HbA1c level.

Preprandial capillary blood glucose: 80 to 130 mg/dL (SI: 4.4 to 7.2 mmol/L) (healthy); 90 to 150 mg/dL (SI: 5 to 8.3 mmol/L) (complex/intermediate health); 100 to 180 mg/dL (SI: 5.6 to 10 mmol/L) (very complex/poor health).

Bedtime capillary blood glucose: 80 to 180 mg/dL (SI: 4.4 to 10 mmol/L) (healthy); 100 to 180 mg/dL (SI: 5.6 to 10 mmol/L) (complex/intermediate health); 110 to 200 mg/dL (SI: 6.1 to 11.1 mmol/L) (very complex/poor health).

Classification of hypoglycemia (ADA 2023):

Level 1: 54 to 70 mg/dL (SI: 3 to 3.9 mmol/L); hypoglycemia alert value; initiate fast-acting carbohydrate (eg, glucose) treatment.

Level 2: <54 mg/dL (SI: <3 mmol/L); threshold for neuroglycopenic symptoms; requires immediate action.

Level 3: Hypoglycemia associated with a severe event characterized by altered mental and/or physical status requiring assistance.

Mechanism of Action

Stimulates insulin release from the pancreatic beta cells; reduces glucose output from the liver; insulin sensitivity is increased at peripheral target sites

Pharmacokinetics (Adult Data Unless Noted)

Duration: 12 to 24 hours

Absorption: Immediate release: Rapid and complete; delayed with food

Distribution: 10 to 11 L

Protein binding: 98% to 99%; primarily to albumin

Bioavailability: 90% to 100%

Metabolism: Hepatic via CYP2C9; forms metabolites (inactive)

Half-life elimination: 2 to 5 hours

Time to peak: 1 to 3 hours; extended release tablets: 6 to 12 hours

Excretion: Urine (<10% as unchanged drug; 80% as metabolites); feces (10%)

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Glipom | Minidiab | Sucrazide;
  • (AR) Argentina: Glipizida gen med | Minodiab;
  • (AT) Austria: Glibenese | Minidiab;
  • (AU) Australia: Melizide | Minidiab;
  • (BD) Bangladesh: Actine | Diactin | Diaplus | Glimerol | Zitrol;
  • (BE) Belgium: Glibenese | Minidiab;
  • (BG) Bulgaria: Antidiab | Glucopress | Minidiab;
  • (BR) Brazil: Glipgen | Glipizida | Minidiab;
  • (CH) Switzerland: Glibenese;
  • (CL) Chile: Minidiab | Xiprine;
  • (CN) China: Di sha | Ge li shu | Ge lie shu | Glipizde | Glutrol | Kang er bi da | Le tou fu | Man di bao | Mei bi da | Minidiab | Mitoneu | Qin su | Sheng qin | Si le ke | Tang ge lie | Tang ke tai | You da ling;
  • (CZ) Czech Republic: Antidiab | Minidiab;
  • (DO) Dominican Republic: Glifel | Minodiab;
  • (EE) Estonia: Antidiab | Glibenese | Glibenese gits | Minidiab;
  • (EG) Egypt: Glibenase | Glupizide | Minidiab;
  • (ES) Spain: Minodiab;
  • (FI) Finland: Apamid | Glibenese | Glipizid generics | Melizid | Mindiab;
  • (FR) France: Glibenese | Glipizide merck | Minidiab;
  • (GB) United Kingdom: Glibenese | Glipizide cox | Glipizide kent | Glipizide Myplan | Glipizide sandoz | Minodiab;
  • (GR) Greece: Glibenese | Minodiab;
  • (HK) Hong Kong: Diasef | Minidiab | Sunglucon;
  • (HU) Hungary: Minidiab;
  • (ID) Indonesia: Aldiab | Glyzid | Minidiab;
  • (IE) Ireland: Glibenese;
  • (IN) India: Bimode | D-glip | Diacon | Diaglip | Dibizide | G-trol | Glez | Glibetic | Glide | Glip | Glipicontin | Glipikem | Glipixor | Glipy | Glucolip | Glucotrol | Glynase | Glyson | Glytop | Glyzip | Lipi | Semi glynase;
  • (IT) Italy: Minidiab;
  • (JO) Jordan: Glibenese | Glipiram | Minidiab | Sucrazide;
  • (KE) Kenya: Diactin | Glipistin;
  • (KR) Korea, Republic of: Digrin | Durimon;
  • (KW) Kuwait: Minidiab;
  • (LB) Lebanon: Minidiab;
  • (LT) Lithuania: Antidiab | Glibenese | Minidiab;
  • (LU) Luxembourg: Glibenese | Minidiab;
  • (LV) Latvia: Glibenese | Minidiab;
  • (MA) Morocco: Minidiab;
  • (MX) Mexico: Flumedil | Gabaz | Glipizida | Glupitel | Luditec | Minodiab | Pigloss | Singloben | Viterob;
  • (MY) Malaysia: Dibizide | Glix | Melizide | Minidiab;
  • (NG) Nigeria: Greelip;
  • (NL) Netherlands: Glibenese;
  • (NO) Norway: Apamid | Glipizid | Mindiab;
  • (NZ) New Zealand: Minidiab;
  • (OM) Oman: Glipom;
  • (PE) Peru: Minidiab;
  • (PH) Philippines: Glipdin | Glucozide | Gluzid | Minidiab;
  • (PK) Pakistan: Glibenese | Glipase | Minidiab;
  • (PL) Poland: Antidiab | Glibenese | Glipizide bp | Minidiab;
  • (PR) Puerto Rico: Glucotrol;
  • (PT) Portugal: Minidiab;
  • (QA) Qatar: Glipom | Sucrazide;
  • (RU) Russian Federation: Antidiab | Glibenese | Glynase | Minidiab | Movogleken;
  • (SA) Saudi Arabia: Minidiab | Sucrazide;
  • (SE) Sweden: Glipiscand | Glipizid meda | Mindiab;
  • (SG) Singapore: Beapizide | Diasef | Glipizide Shin Poong | Melizide | Minidiab | Sunglucon;
  • (SI) Slovenia: Antidiab;
  • (SK) Slovakia: Antidiab | Minidiab;
  • (TH) Thailand: Apamid | Depizide | Diasef | Dipazide | Gipzide | Glibezide | Glimax | Glipidiab | Glipizide nida | Glizide | Glucodiab | Glycediab | Glygen | Gp zide | Melizide | Minibit | Minidiab | Namedia | Topizide | Tozide;
  • (TN) Tunisia: Sucrazide;
  • (TR) Turkey: Minidiab;
  • (TW) Taiwan: Contan | Diabes | Glibetin | Glicon | Glidiab | Glipin | Glix | Glucozide | Glupizide | Glutrol | Loil | Minidiab;
  • (UA) Ukraine: Glynase | Minidiab;
  • (UG) Uganda: Glynase;
  • (VE) Venezuela, Bolivarian Republic of: Minidiab;
  • (VN) Viet Nam: Gliptis;
  • (ZA) South Africa: Minidiab;
  • (ZM) Zambia: Glynase xl
  1. 2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052-2081. doi:10.1111/jgs.18372 [PubMed 37139824]
  2. Abraira C, Henderson WG, Colwell JA, et al. Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM). Diabetes Care. 1998;21(4):574-579. [PubMed 9571345]
  3. Alexopoulos AS, Blair R, Peters AL. Management of preexisting diabetes in pregnancy: a review. JAMA. 2019;321(18):1811-1819. doi:10.1001/jama.2019.4981 [PubMed 31087027]
  4. American College of Obstetricians and Gynecologists (ACOG). ACOG Practice Bulletin No. 201: Pregestational diabetes mellitus. Obstet Gynecol. 2018;132(6):e228-e248. doi: 10.1097/AOG.0000000000002960. [PubMed 15738045]
  5. American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins—Obstetrics. ACOG practice bulletin no. 190: gestational diabetes mellitus. Obstet Gynecol. 2018;131(2):e49-e64. [PubMed 30461693]
  6. American Diabetes Association. 11. Older adults: standards of medical care in diabetes-2018. Diabetes Care. 2018b;41(suppl 1):S119-S125. doi:10.2337/dc18-S011 [PubMed 29222382]
  7. American Diabetes Association (ADA). Standards of care in diabetes–2023. Diabetes Care. 2023;46(suppl 1):S1-S291. https://diabetesjournals.org/care/issue/46/Supplement_1. Accessed May 31, 2023.
  8. American Diabetes Association (ADA). Standards of medical care in diabetes–2021. Diabetes Care. 2021;44(suppl 1):S1-S232. https://care.diabetesjournals.org/content/44/Supplement_1. Accessed January 13, 2021.
  9. American Diabetes Association (ADA). Standards of medical care in diabetes–2022. Diabetes Care. 2022;45(suppl 1):S1-S264. https://care.diabetesjournals.org/content/45/Supplement_1. Accessed May 24, 2022.
  10. Andersen SE, Christensen M. Hypoglycaemia when adding sulphonylurea to metformin: a systematic review and network meta-analysis. Br J Clin Pharmacol. 2016;82(5):1291-1302. doi:10.1111/bcp.13059 [PubMed 27426428]
  11. Apovian CM, Aronne LJ, Bessesen DH, et al; Endocrine Society. Pharmacological management of obesity: an Endocrine Society clinical practice guideline [published correction appears in J Clin Endocrinol Metab. 2015;100(5):2135-2136]. J Clin Endocrinol Metab. 2015;100(2):342-362. doi: 10.1210/jc.2014-3415 [PubMed 25590212]
  12. Arjona Ferreira JC, Corry D, Mogensen CE, et al. Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial. Am J Kidney Dis. 2013b;61(4):579-587. doi:10.1053/j.ajkd.2012.11.043 [PubMed 23352379]
  13. Arjona Ferreira JC, Marre M, Barzilai N, et al. Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency. Diabetes Care. 2013a;36(5):1067-1073. [PubMed 23248197]
  14. Berelowitz M, Fischette C, Cefalu W, Schade DS, Sutfin T, Kourides IA. Comparative efficacy of a once-daily controlled-release formulation of glipizide and immediate-release glipizide in patients with NIDDM. Diabetes Care. 1994;17(12):1460-1464. [PubMed 7882817]
  15. Blumer I, Hadar E, Hadden DR, et al. Diabetes and pregnancy: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013;98(11):4227-4249. [PubMed 24194617]
  16. Bogun M, Inzucchi SE. Inpatient management of diabetes and hyperglycemia. Clin Ther. 2013;35(5):724-733. doi:10.1016/j.clinthera.2013.04.008 [PubMed 23688537]
  17. Brackett CC, Singh H, Block JH. Likelihood and mechanisms of cross-allergenicity between sulfonamide antibiotics and other drugs containing a sulfonamide functional group. Pharmacotherapy. 2004;24(7):856-870. [PubMed 15303450]
  18. Bron M, Wilson C, Fleck P. A post hoc analysis of HbA1c, hypoglycemia, and weight change outcomes with alogliptin vs glipizide in older patients with type 2 diabetes. Diabetes Ther. 2014;5(2):521-534. doi:10.1007/s13300-014-0088-5 [PubMed 25424968]
  19. Cakir M, Akin M, Karayalcin U. Prolonged hypoglycaemia secondary to extended-release form glipizide. Diabetes Obes Metab. 2004;6(4):310-311. doi:10.1111/j.1462-8902.2004.00347.x [PubMed 15171757]
  20. Chow TG, Khan DA. Sulfonamide hypersensitivity. Clin Rev Allergy Immunol. Published online July 1, 2021. doi:10.1007/s12016-021-08872-3 [PubMed 34212341]
  21. Das S, Ramasamy A, De S, Mondal S. An unusual case of glipizide-induced proximal myopathy. J Pharmacol Pharmacother. 2016;7(2):99-101. doi:10.4103/0976-500X.184775 [PubMed 27440956]
  22. Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669-2701. doi:10.2337/dci18-0033 [PubMed 30291106]
  23. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 1999;131(4):281-303. [PubMed 10454950]
  24. Del Prato S, Camisasca R, Wilson C, Fleck P. Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year study. Diabetes Obes Metab. 2014;16(12):1239-1246. doi:10.1111/dom.12377 [PubMed 25132212]
  25. Deusenberry CM, Coley KC, Korytkowski MT, Donihi AC. Hypoglycemia in hospitalized patients treated with sulfonylureas. Pharmacotherapy. 2012;32(7):613-617. doi:10.1002/j.1875-9114.2011.01088.x [PubMed 22570146]
  26. Diabetes Canada Clinical Practice Guidelines Expert Committee. Diabetes Canada 2018 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes. 2018;42(suppl 1):S1-S325.
  27. Douros A, Yin H, Yu OHY, Filion KB, Azoulay L, Suissa S. Pharmacologic differences of sulfonylureas and the risk of adverse cardiovascular and hypoglycemic events. Diabetes Care. 2017;40(11):1506-1513. doi:10.2337/dc17-0595 [PubMed 28864502]
  28. Egan AM, Dow ML, Vella A. A review of the pathophysiology and management of diabetes in pregnancy. Mayo Clin Proc. 2020;95(12):2734-2746. doi:10.1016/j.mayocp.2020.02.019 [PubMed 32736942]
  29. Elliott BD, Schenker S, Langer O, et al. Comparative placental transport of oral hypoglycemic agents in humans: a model of human placental drug transfer. Am J Obstet Gynecol. 1994;171(3):653-660. [PubMed 8092211]
  30. Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.
  31. Feig DS, Briggs GG, Kraemer JM, et al. Transfer of glyburide and glipizide into breast milk. Diabetes Care. 2005;28(8):1851-1855. [PubMed 16043722]
  32. Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary. Endocr Pract. 2020;26(1):107-139. doi:10.4158/CS-2019-0472 [PubMed 32022600]
  33. Gianchandani RY, Neupane S, Iyengar JJ, Heung M. Pathophysiology and management of hypoglycemia in end-stage renal disease patients: a review. Endocr Pract. 2017;23(3):353-362. [PubMed 27967230]
  34. Glipizide tablets [prescribing information]. Baudette, MN: ANI Pharmaceuticals Inc; April 2022.
  35. Glucotrol XL (glipizide) [prescribing information]. New York, NY: Pfizer; November 2021.
  36. Gökalp O, Gunes A, Cam H, et al. Mild hypoglycaemic attacks induced by sulphonylureas related to CYP2C9, CYP2C19 and CYP2C8 polymorphisms in routine clinical setting. Eur J Clin Pharmacol. 2011;67(12):1223-1229. doi:10.1007/s00228-011-1078-4 [PubMed 21691805]
  37. Golightly LK, Teitelbaum I, Kiser TH, et al, eds. Renal Pharmacotherapy: Dosage Adjustment of Medications Eliminated by the Kidneys. New York, NY: Springer Science; 2013.
  38. Hurren KM, Bartley EP, O'Neill JL, Ronis DL. Effect of sulfonylurea dose escalation on hemoglobin A1c in Veterans Affairs patients with type 2 diabetes. Acta Diabetol. 2013;50(2):261-265. doi: 10.1007/s00592-010-0197-1. [PubMed 20512383]
  39. Ilario MJ, Turyan HV, Axiotis CA. Glipizide treatment with short-term alcohol abuse resulting in subfulminant hepatic failure. Virchows Arch. 2003;443(1):104-105. doi:10.1007/s00428-003-0793-3 [PubMed 12719973]
  40. Inzucchi SE. Clinical practice. Management of hyperglycemia in the hospital setting. N Engl J Med. 2006;355(18):1903-1911. doi:10.1056/NEJMcp060094 [PubMed 17079764]
  41. Johnson KK, Green DL, Rife JP, Limon L. Sulfonamide cross-reactivity: fact or fiction? [published correction appears in Ann Pharmacother. 2005;39(7-8):1373]. Ann Pharmacother. 2005;39(2):290-301. [PubMed 15644481]
  42. Khan DA, Knowles SR, Shear NH. Sulfonamide hypersensitivity: fact and fiction. J Allergy Clin Immunol Pract. 2019;7(7):2116-2123. doi:10.1016/j.jaip.2019.05.034 [PubMed 31495421]
  43. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2020;98(4S):S1-S115. doi:10.1016/j.kint.2020.06.019 [PubMed 32998798]
  44. Korner J, Inabnet W, Febres G, et al. Prospective study of gut hormone and metabolic changes after adjustable gastric banding and Roux-en-Y gastric bypass. Int J Obes (Lond). 2009;33(7):786-795. doi: 10.1038/ijo.2009.79 [PubMed 19417773]
  45. Leonard CE, Han X, Brensinger CM, et al. Comparative risk of serious hypoglycemia with oral antidiabetic monotherapy: a retrospective cohort study. Pharmacoepidemiol Drug Saf. 2018;27(1):9-18. doi:10.1002/pds.4337 [PubMed 29108130]
  46. LeRoith D, Biessels GJ, Braithwaite SS, et al. Treatment of diabetes in older adults: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2019;104(5):1520-1574. doi: 10.1210/jc.2019-00198. [PubMed 30903688]
  47. Mechanick JI, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures - 2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, the Obesity Society, American Society for Metabolic & Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. Surg Obes Relat Dis. 2020;16(2):175-247. doi:10.1016/j.soard.2019.10.025 [PubMed 31917200]
  48. Mingrone G, Cummings DE. Changes of insulin sensitivity and secretion after bariatric/metabolic surgery. Surg Obes Relat Dis. 2016;12(6):1199-1205. doi: 10.1016/j.soard.2016.05.013. [PubMed 27568471]
  49. Moghissi ES, Korytkowski MT, DiNardo M, et al; American Association of Clinical Endocrinologists; American Diabetes Association. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Endocr Pract. 2009;15(4):353-369. doi:10.4158/EP09102.RA [PubMed 19454396]
  50. National Kidney Foundation. KDOQI clinical practice guidelines for diabetes and CKD: 2012 update. Am J Kidney Dis. 2012;60(5):850-886. doi: 10.1053/j.ajkd.2012.07.005. [PubMed 23067652]
  51. Parekh TM, Raji M, Lin YL, Tan A, Kuo YF, Goodwin JS. Hypoglycemia after antimicrobial drug prescription for older patients using sulfonylureas. JAMA Intern Med. 2014;174(10):1605-1612. doi:10.1001/jamainternmed.2014.3293 [PubMed 25179404]
  52. Peterli R, Steinert RE, Woelnerhanssen B, et al. Metabolic and hormonal changes after laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy: a randomized, prospective trial. Obes Surg. 2012;22(5):740-748. doi: 10.1007/s11695-012-0622-3. [PubMed 22354457]
  53. Reader D, Franz MJ. Lactation, diabetes, and nutrition recommendations. Curr Diab Rep. 2004;4(5):370-376. [PubMed 15461903]
  54. Refer to manufacturer's labeling.
  55. Romley JA, Gong C, Jena AB, Goldman DP, Williams B, Peters A. Association between use of warfarin with common sulfonylureas and serious hypoglycemic events: retrospective cohort analysis. BMJ. 2015;351:h6223. doi:10.1136/bmj.h6223 [PubMed 26643108]
  56. Samson SL, Vellanki P, Blonde L, et al. American Association of Clinical Endocrinology consensus statement: comprehensive type 2 diabetes management algorithm – 2023 update. Endocr Pract. 2023;29(5):305-340. doi:10.1016/j.eprac.2023.02.001 [PubMed 37150579]
  57. Schaefer-Graf UM, Hartmann R, Pawliczak J,et al. Association of breast-feeding and early childhood overweight in children from mothers with gestational diabetes mellitus. Diabetes Care. 2006;29(5):1105-1107. [PubMed 16644645]
  58. Schelleman H, Han X, Brensinger CM, et al. Pharmacoepidemiologic and in vitro evaluation of potential drug-drug interactions of sulfonylureas with fibrates and statins. Br J Clin Pharmacol. 2014;78(3):639-648. doi:10.1111/bcp.12353 [PubMed 24548191]
  59. Schopman JE, Simon AC, Hoefnagel SJ, Hoekstra JB, Scholten RJ, Holleman F. The incidence of mild and severe hypoglycaemia in patients with type 2 diabetes mellitus treated with sulfonylureas: a systematic review and meta-analysis. Diabetes Metab Res Rev. 2014;30(1):11-22. doi:10.1002/dmrr.2470 [PubMed 24030920]
  60. Segel SA, Paramore DS, Cryer PE. Hypoglycemia-associated autonomic failure in advanced type 2 diabetes. Diabetes. 2002;51(3):724-733. doi:10.2337/diabetes.51.3.724 [PubMed 11872673]
  61. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern Med. 1997;157(15):1681-1686. [PubMed 9250229]
  62. Slatore CG, Tilles SA. Sulfonamide hypersensitivity. Immunol Allergy Clin North Am. 2004;24(3):477-490. [PubMed 15242722]
  63. Stenman S, Melander A, Groop PH, Groop LC. What is the benefit of increasing the sulfonylurea dose? Ann Intern Med. 1993;118(3):169-172. [PubMed 8417634]
  64. Sulfonamide cross-reactivity. Med Lett Drugs Ther. 2019;61(1568):44-46. [PubMed 31022157]
  65. Tandra S, Chalasani N, Jones DR, Mattar S, Hall SD, Vuppalanchi R. Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. Ann Surg. 2013;258(2):262-269. doi: 10.1097/SLA.0b013e31827a0e82 [PubMed 23222033]
  66. Tornero P, De Barrio M, Baeza ML, Herrero T. Cross-reactivity among p-amino group compounds in sulfonamide fixed drug eruption: diagnostic value of patch testing. Contact Dermatitis. 2004;51(2):57-62. [PubMed 15373844]
  67. Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: a report from an ADA consensus conference. Diabetes Care. 2014;37(10):2864-2883. doi: 10.2337/dc14-1296. [PubMed 25249672]
  68. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [published correction appears in: Lancet. 1999;354(9178):602]. Lancet. 1998;352(9131):837-853. [PubMed 9742976]
  69. van Staa T, Abenhaim L, Monette J. Rates of hypoglycemia in users of sulfonylureas. J Clin Epidemiol. 1997;50(6):735-741. doi:10.1016/s0895-4356(97)00024-3 [PubMed 9250272]
  70. Wåhlin-Boll E, Sartor G, Melander A, Scherstén B. Impaired effect of sulfonylurea following increased dosage. Eur J Clin Pharmacol. 1982;22(1):21-25. [PubMed 7047168]
  71. Wexler DJ. Sulfonylureas and meglitinides in the treatment of type 2 diabetes mellitus. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed May 24, 2022.
Topic 8492 Version 588.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟